絞り込み

16404

広告

神戸マラソンに約2万人 健脚競う (NHK)

阪神・淡路大震災で受けた支援への感謝と復興した町の様子を伝えようと始まった神戸マラソンが19日に行われ、およそ2万人が健脚を競いました。 神戸マラソンはことしで...

  1. 食物アレルギー 治療や検査で9人が重い症...
  2. 冬の登山に注意を 富士山登山道で呼びかけ...
  3. 歴史教科書、龍馬が消える? 高校の用語半...
  4. クルマ社会に革新をもたらす10の「注目ス...

ニュース一覧

Anti-thrombotic therapy for atrial fibrillation in patients with chronic kidney disease: Current views.

著者 Ghadban R , Flaker G , Katta N , Alpert MA
Hemodial Int.2017 Oct ; 21 Suppl 2():S47-S56.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (32view , 0users)

Full Text Sources

Miscellaneous

Chronic kidney disease (CKD) occurs in approximately one-third of patients with non-valvular atrial fibrillation (AF). The presence of CKD, particularly advanced CKD, confers increased risk of both thromboembolism and major bleeding in this group of patients who are already at risk for ischemic stroke and systemic embolism and at risk of bleeding due to anticoagulation. Studies assessing the effect of warfarin on risk of ischemic stroke, systemic embolism, and major bleeding have produced disparate results, particularly in patients with advanced CKD including those treated with hemodialysis. The direct oral anticoagulants (DOAC's) have been studied in patients with stage III (moderate) CKD and appear to be as effective or more effective (dabigatran 150 mg twice daily) than warfarin in preventing ischemic stroke or embolism in this group. Two of the DOAC's, apixaban and edoxaban, confer lower risk of major bleeding than warfarin with appropriate dose adjustments. Substantial gaps exist in our knowledge of anti-thrombotic therapy in patients with AF and CKD, primarily due to exclusion of patients with advanced CKD from randomized controlled trials comparing DOAC's with warfarin.
PMID: 29064182 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード